Statistics from Altmetric.com
Lumiracoxib is a selective cyclo-oxygenase 2 (COX-2) inhibitor used for symptomatic treatment of osteoarthritis and acute pain. Among the available COX-2 inhibitors, lumiracoxib is the only compound with gastrointestinal benefit in patients with osteoarthritis that has been demonstrated in a large outcome study.1
Several countries have approved lumiracoxib at doses of 200 mg (for osteoarthritis) and 400 mg (for acute pain), both of them exceeding the dose necessary to inhibit COX-2 at the time of maximal plasma concentration.2 In line with this notion, one clinical trial reported that patients with knee or hip osteoarthritis randomised to receive lumiracoxib at 50, 100 or 200 mg twice daily or at 400 mg once daily experienced a comparable pain relief.3 Regrettably, a systematical analysis of dose-dependent therapeutic effects of lumiracoxib is lacking.
The interest in …
Competing interests: BH has received consulting fees/honoraria from Astra-Zeneca and Novartis, and has received research support from Bayer. KB has received consulting fees/honoraria from Bayer, Merck, Sharp & Dohme and Novartis, and has received research support from Aventis, Bayer, Merck, Shorp & Dohme and Novartis. BR has received research support from Merck, Sharp & Dohme, GlaxoSmithKline and Philip Morris USA.
BH and BR contributed equally to this work.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.